Stocks and InvestingStocks and Investing
Fri, May 14, 2021
Thu, May 13, 2021
Wed, May 12, 2021
Tue, May 11, 2021

Raghuram Selvaraju Maintained (BTAI) at Strong Buy with Decreased Target to $170 on, May 11th, 2021


Published on 2024-10-27 16:38:10 - WOPRAI, Raghuram Selvaraju
  Print publication without navigation


Raghuram Selvaraju of HC Wainwright & Co., Maintained "BioXcel Therapeutics, Inc." (BTAI) at Strong Buy with Decreased Target from $175 to $170 on, May 11th, 2021.

Raghuram has made no other calls on BTAI in the last 4 months.



There are 4 other peers that have a rating on BTAI. Out of the 4 peers that are also analyzing BTAI, 0 agree with Raghuram's Rating of Hold.



These are the ratings of the 4 analyists that currently disagree with Raghuram


  • Anita Dushyanth of "Berenberg" Initiated at Strong Buy and Held Target at $75 on, Friday, April 9th, 2021
  • Robyn Karnauskas of "Truist Securities" Maintained at Strong Buy with Decreased Target to $127 on, Thursday, April 1st, 2021
  • Sumant Kulkarni of "Canaccord Genuity" Maintained at Strong Buy with Decreased Target to $95 on, Thursday, April 1st, 2021
  • Colin Bristow of "UBS" Initiated at Strong Buy and Held Target at $99 on, Monday, February 1st, 2021